Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections

NCT ID: NCT03827694

Last Updated: 2024-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-30

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Invasive Fungal Infections Pulmonary Invasive Aspergillosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with possible PIFI

Non-Invasive Testing for PIFI

Intervention Type DIAGNOSTIC_TEST

galactomannan assay, fungal PCRs, cell-free next-generation DNA/RNA sequencing, RNAseq

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-Invasive Testing for PIFI

galactomannan assay, fungal PCRs, cell-free next-generation DNA/RNA sequencing, RNAseq

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females age \> 120 days and \< 22 years at any participating site
* Have at least one of the following conditions associated with a known high incidence of IFI: hematopoietic stem cell transplantation (HSCT), aplastic anemia, bone marrow failure, primary or acquired immune deficiency, or malignancy
* New (last 96 hours) radiographic evidence of at least one of the following: at least one nodular lesion greater than or equal to 5 mm in size, a wedge-shaped and segmental or lobar consolidation, a cavitary lesion, a lesion with a halo sign, a lesion with a reverse halo sign, or a lesion with an air crescent sign
* Prolonged neutropenia (absolute neutrophil count \< 500 cells/µl for a period of ≥ 5 consecutive days) in 30 days prior to and including the day of qualifying chest MRI or CT scan date OR currently receiving systemic therapy for acute or chronic graft-versus-host disease (GVHD) OR presence of neutrophil dysfunction because of underlying acquired or primary immune deficiency (e.g. chronic granulomatous disease) on the date of the qualifying chest MRI or CT scan
* Subject consent or parental/guardian permission (informed consent) and if appropriate, child assent

Exclusion Criteria

* Weight \<3 kg, so as to not exceed 3 ml/kg in a single blood draw
* Previous inclusion in this study
Minimum Eligible Age

120 Days

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Children's Hospital of Philadelphia

OTHER

Sponsor Role collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role collaborator

Arkansas Children's Hospital Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William Steinbach

Role: PRINCIPAL_INVESTIGATOR

University of Arkansas

Brian Fisher

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital of Philadelphia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arkansas Children's Research Institute

Little Rock, Arkansas, United States

Site Status RECRUITING

Rady Children's Hospital, UCSD

La Jolla, California, United States

Site Status RECRUITING

Children's Hospital of Orange County

Orange, California, United States

Site Status RECRUITING

Lucile Packard Children's Hospital, Stanford University

Palo Alto, California, United States

Site Status RECRUITING

University of California San Francisco, Benioff Children's Hospital

San Francisco, California, United States

Site Status WITHDRAWN

Yale University

New Haven, Connecticut, United States

Site Status RECRUITING

Children's National Hospital

Washington D.C., District of Columbia, United States

Site Status RECRUITING

All Children's Research Institute

St. Petersburg, Florida, United States

Site Status ACTIVE_NOT_RECRUITING

Emory University-Children's Healthcare of Atlanta (CHOA)

Atlanta, Georgia, United States

Site Status RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Site Status RECRUITING

University of Chicago Medicine, Comer Children's

Chicago, Illinois, United States

Site Status RECRUITING

Indiana University School of Medicine

Indianapolis, Indiana, United States

Site Status RECRUITING

Boston Children's Hospital

Boston, Massachusetts, United States

Site Status RECRUITING

University of Minnesota Medical School

Minneapolis, Minnesota, United States

Site Status ACTIVE_NOT_RECRUITING

Children's Minnesota

Saint Paul, Minnesota, United States

Site Status RECRUITING

Children's Mercy

Kansas City, Missouri, United States

Site Status RECRUITING

The Washington University

St Louis, Missouri, United States

Site Status RECRUITING

Children's Omaha

Omaha, Nebraska, United States

Site Status RECRUITING

Weil Cornell Medical College

New York, New York, United States

Site Status RECRUITING

Duke University Medical Center

Durham, North Carolina, United States

Site Status ACTIVE_NOT_RECRUITING

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Site Status RECRUITING

Cleveland Clinic

Cleveland, Ohio, United States

Site Status WITHDRAWN

Nationwide Children's Hospital

Columbus, Ohio, United States

Site Status RECRUITING

Oregon Health and Science University

Portland, Oregon, United States

Site Status RECRUITING

The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

St. Jude Children's Research Hospital

Memphis, Tennessee, United States

Site Status RECRUITING

Monroe Carell Jr. Children's Hospital at Vanderbilt

Nashville, Tennessee, United States

Site Status RECRUITING

Ascension Seton Medical Center

Austin, Texas, United States

Site Status RECRUITING

University of Texas Southwest Medical Center (UTSW)

Dallas, Texas, United States

Site Status RECRUITING

MD Anderson

Houston, Texas, United States

Site Status RECRUITING

Seattle Children's Research Institute

Seattle, Washington, United States

Site Status RECRUITING

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status RECRUITING

The Hospital for Sick Children

Toronto, Ontario, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

PFN Central Coordinator

Role: CONTACT

501-364-3057

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01AI139032

Identifier Type: NIH

Identifier Source: secondary_id

View Link

Pro00094558

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Itraconazole Therapy In Bronchiectasis With Airway Mold
NCT07283497 NOT_YET_RECRUITING PHASE4
Treatment Duration of IPA
NCT06583512 ACTIVE_NOT_RECRUITING